Amgen, a global biopharmaceutical giant, has just launched its first Scholars Program in India with an inaugural cohort of just 10 undergraduate students, signaling a focused, long-term bet on AI talent for drug discovery. The program aims to cultivate specialized skills directly, rather than competing for existing experts. The program at the International Institute of Information Technology (IIIT) Hyderabad includes scholars from India, Vietnam, Qatar, and Dubai, according to Express Pharma.
Global pharmaceutical companies increasingly rely on advanced AI/ML capabilities for drug discovery. However, the highly specialized talent needed to integrate these technologies is scarce and requires significant long-term cultivation.
Strategic, localized programs like Amgen's in India are likely to become a critical model for biopharma companies seeking to cultivate specialized AI/ML talent and accelerate R&D pipelines globally, despite their initially modest scale.
- Amgen launched its first Scholars Program in India at the International Institute of Information Technology (IIIT) Hyderabad, according to Express Pharma.
- The inaugural cohort comprises 10 undergraduate scholars from India, Vietnam, Qatar, and Dubai, as reported by BioSpectrum India.
- This two-month residential program focuses on AI, machine learning, and scientific research, states Telangana Today.
- Amgen supports this program through summer 2027.
- Scholars will explore artificial intelligence and machine learning applications in fundamental sciences, drug design, healthcare, cheminformatics, and genomics.
Cultivating Future AI Leaders for Drug Discovery
Scholars will explore artificial intelligence and machine learning applications across fundamental sciences, drug design, healthcare, cheminformatics, and genomics, according to Express Pharma. The broad academic focus demonstrates Amgen's investment in both theoretical and exploratory AI/ML aspects for drug discovery.
